Navigation Links
Biodel Reports First Quarter Fiscal Year 2011 Financial Results
Date:2/3/2011

n in other income as a result of the revaluation.

Expenses for the three months ended December 31, 2010 and 2009 include $1.5 and $1.3 million, respectively in stock-based compensation expense related to options granted to employees and non-employees.

Biodel did not recognize any revenue during the three months ended December 31, 2010 or 2009.

At December 31, 2010, Biodel had cash and cash equivalents of $22.3 million and 26.4 million shares outstanding.  

Business Review

Biodel recently met with staff from the U.S. Food and Drug Administration (FDA) on January 28, 2011 to discuss the agency's October 29, 2010 complete response letter regarding the NDA for Linjeta™ and to explore appropriate next steps for the ultra-rapid-acting prandial insulin program.  The End of Review Meeting addressed questions posed by Biodel in response to the FDA's complete response letter.  During the meeting the FDA considered questions posed by Biodel to help define paths forward regarding clinical trial design, injection site tolerability, toxicology and chemistry, manufacturing and controls.

Since the Linjeta™ NDA was submitted in December 2009, Biodel has developed and tested new formulations of Linjeta™ that maintain its favorable pharmacokinetic profile for speed of activity and stability and may improve injection site tolerability.  Based upon encouraging early results from these studies, Biodel has decided to fund clinical development of several alternative formulations of Linjeta™ with the goal of determining the preferred formulation and advancing it into Phase 2 clinical testing in 2012.

The company has decided to focus most of its resources on the ultra-rapid-acting prandial insulin program and to limit funding of its earlier-stage development programs, which include a glucose-sensing basal insulin formulation, a glargine formulation with improved basal characteristics, a stable liqu
'/>"/>

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Biodel to Report First Quarter Fiscal Year 2011 Financial Results on February 3, 2011
2. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
3. Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer
4. Biodel Reports Fourth Quarter and Fiscal Year 2010 Financial Results
5. Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting
6. Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting
7. Biodel Awarded $1.2 Million in Therapeutic Discovery Research Grants From IRS
8. FDA Issues Complete Response Letter to Biodel Regarding New Drug Application for Linjetaâ„¢
9. Biodel to Present at Upcoming Conferences
10. Biodel Reports Research Progress in Poster Session on Short-Acting Insulins at 46th EASD Annual Meeting
11. Biodel Appoints Arthur Urciuoli to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 2014 The following is being released ... The Green Park Collaborative (GPC) will bring ... payers, medical device and pharmaceutical companies, as well ... 12, 2015 at its first ever workshop on ... treatments.  Participants will discuss study designs to evaluate ...
(Date:10/17/2014)...  UBM Medica US announces that Endocrinology Network ... clinicians who treat patients with type 2 diabetes ... of insulin .  Nearly all patients ... – daily injections of one or more insulin ... function of pancreatic beta cells. Insulin is a very ...
(Date:10/17/2014)... -- Ameritox SM , the nation,s leader in medication monitoring ... , M.D., as Chief Medical Officer. In this role, ... for healthcare providers, patients and managed care plans.   ... variety of healthcare companies that have provided him with ... health sides of Ameritox,s business. He most recently served ...
Breaking Medicine Technology:Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3Ameritox Appoints New Chief Medical Officer 2
... Visica 2(TM) Treatment System Selected as Exclusive Cryoablation ... ... The American College of,Surgeons Oncology Group (ACOSOG) which just ... Phase II Trial Exploring,the Success of Cryoablation Therapy in the ...
... results to be presented at 2008 ICAAC/IDSA ... Sequella, Inc., a,clinical-stage biopharmaceutical company focused ... epidemic potential, announces the,successful demonstration of synergistic ... resulting from in vitro combination,studies of Sequella ...
Cached Medicine Technology:NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 2NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 3Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207 2
(Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
(Date:10/20/2014)... 2014 National Teen Driver Safety Week is ... Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining ... of teen drivers to talk to their teens and always ... vehicle crashes are the leading cause of death for U.S. ... fatal crashes, and 859 (42%) of those teen drivers were ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
(Date:10/19/2014)... New York (PRWEB) October 19, 2014 ... Nations Population Fund, welcomes news of a ceasefire agreement ... the more than 200 girls who were kidnapped from ... girls have languished in captivity long enough, and it ... schools and communities," stated Dr. Osotimehin. , "We owe ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 SweetDressy.com, a ... recently announced its promotion for long evening dresses ... enjoy the special offer; the current discount is up ... of the industry pioneers in the fashion field. Its ... for ladies dwelling in various parts of the world. ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... Zephyr(R) EBV Technology Enables Pulmonx to Develop Both ... ALTO, Calif., May 13 Pulmonx, a medical ... with emphysema, announced today that it has acquired ... its endobronchial valve (EBV) technology platform and associated ...
... Technologies Limited (ASX: TEO), a global healthcare company, ... catheter it is developing with Vascular Pathways, Inc., ... Award. , "Telesso is pleased to receive another ... may revolutionize peripheral IV placement," said Telesso,s CEO ...
... Zimmer Holdings, Inc. (NYSE: ZMH ; SWX: ... Bank 34th Annual Health Care Conference in Boston, Massachusetts, on ... of the presentation can be accessed via Zimmer,s Investor Relations ... The webcast will be archived for replay following the conference. ...
... that it has enrolled its 1,000th patient into its ... esponsiveness with A V erifyNow(R) Assay I ... S afety). The trial is specifically designed to demonstrate ... patients who are poor responders to clopidogrel (Plavix(R)). The ...
... ESRX ) announced that it will present at ... 19, 2009 at 10:10 a.m. EDT at the InterContinental Hotel ... Internet and can be accessed on the investor relations section ... RealPlayer or Windows Media Player is needed to listen to ...
... reduced in rodent models of liver injury, leading ... two factors that contribute to endothelial dysfunction and ... the analysis of the human Cystathionase gene promoter ... Administration of an FXR ligand to carbon tetrachloride ...
Cached Medicine News:Health News:Pulmonx Acquires Assets of Emphasys Medical and Unveils Combined Product Portfolio at International Conference of the American Thoracic Society (ATS) Annual Meeting 2Health News:Pulmonx Acquires Assets of Emphasys Medical and Unveils Combined Product Portfolio at International Conference of the American Thoracic Society (ATS) Annual Meeting 3Health News:Accumetrics, Inc. Announces 1000th Patient Enrolled in GRAVITAS Trial 2Health News:Farnesoid X receptor regulates cystathionase 2
...
...
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 35G x 5/8in (.50 x 16mm)...
Medicine Products: